



## Living Cell Technologies Limited

### COMPANY ANNOUNCEMENT

#### **Working with the Ministry of Health on New Zealand clinical trial of DIABECCELL<sup>®</sup>**

**17 April 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)** On 21 October 2008 the New Zealand Minister of Health authorised an application from the company to conduct a clinical trial of DIABECCELL<sup>®</sup> in New Zealand. As stated at the time, the approval was subject to conditions designed to safeguard the health and safety of the trial's participants and the wider public. One of these conditions was completion of an international peer review to advise the Minister on the adequacy of LCT's application and the risk management and safety procedures in the protocol and to make recommendations on whether any changes are required to the conditions of approval placed on the study in order to adequately manage any outstanding risk of patient harm.

The peer reviewer has asked for further information about the safety of the proposed trial. LCT has provided a response for consideration by the peer reviewer and understands that the review of the additional data provided will be completed by early May.

LCT is continuing to monitor the seven patients in the on-going trial in Russia and is planning further implants. Product quality specifications have been narrowed and indications from the last implant reported early this month, where the patient has gone off insulin altogether, are very promising.

The new pig breeding facility is expected to be completed in the next four to six weeks. When fully commissioned, the new facility advances LCT's capability to supply pig cells for the next two years of the Company's clinical program and supports LCT's leading position in this field.

-Ends-

#### **For further information:**

Dr. Paul Tan  
Chief Executive Officer  
Mob: 0402 716 984 (AUS)  
Mob: 021 608 784 (NZ)  
Tel: +64 9 270 794

Mr John Cowan  
Finance & Administration Manager  
Tel: +64 9 276 2690  
[jcowan@lctglobal.com](mailto:jcowan@lctglobal.com)

Prof. Bob Elliott  
Medical Director  
Mob: +64 27 292 4177  
Tel: +64 9 276 2690  
[relliott@lctglobal.com](mailto:relliott@lctglobal.com)

Rebecca Wilson  
Investor and Media Relations (ANZ)  
Mob: +61 417 382 391  
Tel: +61 3 9866 4722  
[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

#### **About Living Cell Technologies: [www.lctglobal.com](http://www.lctglobal.com)**

*Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the*



*need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For Parkinson's disease, Huntington's disease and other neurological disorders, the company is developing microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.*

**LCT Disclaimer**

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of April 2009 and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.